Agent Capital is a healthcare investment firm focused on novel technologies and therapeutics that address unmet patient need. Our investment areas of focus are new products and technologies for oncology, immunology, neurology and rare disease indications. We make direct equity investments across all stages of development and types of financing rounds.
Location: United States, Massachusetts, Waltham
Employees: 1-10
Founded date: 2016
Investment Type: Venture Capital
Portfolio 19
| Date | Name | Website | Total Raised | Location |
| 27.04.2023 | Foresight ... | foresight-dx.com | $132.75M | United Sta... |
| 22.06.2022 | Carbon Bio... | carbonbio.com | $38M | United Sta... |
| - | Orbus Ther... | orbustherapeutics.com | $103.5M | Canada |
| - | Interius | interiusbio.com | $76M | United Sta... |
| - | Freenome | freenome.com | $1.05B | United Sta... |
| - | Carisma Th... | carismatx.com | $159M | United Sta... |
| - | Precision ... | precisionbiosciences.com | $135.6M | United Sta... |
| - | Pliant The... | pliantrx.com | $207M | United Sta... |
| - | Orchard Th... | orchard-tx.com | $706M | United Kin... |
| - | Aptinyx In... | aptinyx.com | $135M | United Sta... |
Show more
Mentions in press and media 12
| Date | Title | Description |
| 22.10.2025 | EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion | EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion Wed, Oct 22, 2025 09:20 CET Report this content Ipsen and ImCheck Therapeutics have entered into a definitive share purchase agre... |
| 12.10.2025 | Star Therapeutics: $125 Million Series D Raised For Developing Antibodies For Bleeding Disorders | Star Therapeutics, an innovative clinical-stage biotechnology company, is dedicated to discovering and developing cutting-edge antibodies aimed at treating bleeding disorders and other medical conditions. The company recently announced the ... |
| 01.10.2025 | Star Therapeutics Raises $125M in Series D Financing | Star Therapeutics, a San Francisca, CA-based clinical stage biotechnology company discovering and developing antibodies for bleeding disorders and other diseases, raised $125M Series D funding. The round was co-led by Sanofi Ventures and Vi... |
| 30.05.2025 | GlycoEra AG: Pioneering a New Era in Autoimmune Disease Treatment | In the world of biotechnology, innovation is the lifeblood that fuels progress. GlycoEra AG is a shining example of this principle. Recently, the company secured $130 million in funding to advance its groundbreaking therapies for autoimmune... |
| 27.05.2025 | GlycoEra AG raises $130 Million to advance therapies for autoimmune diseases | GlycoEra’s proprietary platform enables the development of best-in-class degraders that target a broad spectrum of extracellular proteins. GlycoEra’s degraders are bispecific molecules that leverage a naturally occurring process to degrade... |
| 03.02.2025 | Hone Health: $33 Million (Series A) Raised And ivee Acquisition | Hone Health, a leading telehealth clinic specializing in preventative and proactive longevity care, announced that it crossed 300,000 patients tested, 55,000 patients treated, and completed a $33 million Series A funding round with particip... |
| 31.01.2025 | Hone Health Raises $33M to Make Aging Optional | In an era where chronic diseases increasingly impact quality of life, the healthcare system continues to focus on reactive treatment rather than prevention. Many individuals in their mid-30s and beyond experience symptoms like weight gain, ... |
| 29.01.2025 | SafelyYou secures $43M for AI-assisted senior living and more funding news | Photo: Halfpoint Images/Getty Images SafelyYou, maker of AI-enabled technology for fall detection and prevention, closed a $43 million Series C funding round led by Touring Capital, bringing its total raise to more than $100 million. Samsun... |
| 23.11.2024 | TRexBio: $84 Million (Series B) Closed To Decode Human Tissue Immune Biology | TRex Bio – a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics – announced the closing of an oversubscribed $84 million Series B funding round. This funding was led by Delos Capital, with additi... |
| 25.04.2024 | Cerevance Secures $47M to Drive Innovation in CNS Therapeutics | Cerevance, a Boston-based company specializing in precision treatments for central nervous system (CNS) disorders, recently closed a $47 million Series B-1 Extension financing round. The funding, led by Agent Capital, Bioluminescence Ventur... |
Show more